SCHEMBL3014833

SCHEMBL3014833

O=S(=O)(c1ccc(Cl)c(Cl)c1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 1/20 0.34
PROKR1 Q8TCW9 3/20 0.34
FPR2 P25090 2/20 0.34
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
KCNH2 Q12809 2/20 0.34
DRD2 P14416 1/20 0.34
AR P10275 1/20 0.34
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GRM5 P41594 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007633 0.95 CACNA1G (0.36) L3MBTL1LMNASMN1; SMN2ALDH1A1HTR2A
SCHEMBL3004485 0.95 HTR2A (0.36) L3MBTL1SMN1; SMN2ALDH1A1PROKR1FPR2
SCHEMBL3011357 0.94 L3MBTL1 (0.36) L3MBTL1LMNASMN1; SMN2ALDH1A1HTR2A
SCHEMBL3016860 0.94 L3MBTL1 (0.36) L3MBTL1LMNASMN1; SMN2ALDH1A1HTR2A
SCHEMBL3013801 0.93 L3MBTL1 (0.39) L3MBTL1LMNASMN1; SMN2ALDH1A1HTR2A
SCHEMBL3011420 0.93 HTR2A (0.42) L3MBTL1SMN1; SMN2ALDH1A1PROKR1FPR2
SCHEMBL3007239 0.93 HTR2A (0.40) L3MBTL1SMN1; SMN2ALDH1A1PROKR1FPR2
SCHEMBL3015894 0.92 MAPT (0.35) L3MBTL1LMNASMN1; SMN2ALDH1A1PROKR1
SCHEMBL3010530 0.91 HTR2A (0.35) L3MBTL1SMN1; SMN2ALDH1A1PROKR1FPR2
SCHEMBL3017935 0.91 HTR2A (0.35) L3MBTL1LMNASMN1; SMN2ALDH1A1PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885LMNA 80/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.